UN Backs Delinkage in Political Declaration of the High-Level Meeting of the General Assembly on Antimicrobial Resistance

Posted on 30 September 201615 November 2016 by James Love

A September 21, 2016 high level meeting of the United Nations General Assembly on antimicrobial resistance endorsed delinking the cost of R&D from the price and volume of sales. The documents from the meeting are available here: http://www.un.org/pga/71/event-latest/high-level-meeting-on-antimicrobial-resistance/. The relevant part of the political declaration was as follows: (c) Underline also that all research and Read more about UN Backs Delinkage in Political Declaration of the High-Level Meeting of the General Assembly on Antimicrobial Resistance[…]

Group of 77 and China Back Delinkage in Context of Antimicrobials

Posted on 30 September 201615 November 2016 by James Love

During the UN high level meeting on Antimicrobial Resistance, the Group of 77 and and China read a statement that included an endorsement of delinkage: Statement delivered by His Excellency General Prayut Chan-o-cha (ret.) Prime Minister of the Kingdom of Thailand on behalf of the Group of 77 and China at the Plenary of the Read more about Group of 77 and China Back Delinkage in Context of Antimicrobials[…]

UN High-Level Panel Endorses Delinkage of R&D Costs from Prices of Drugs and Vaccines

Posted on 14 September 201616 September 2016 by Zack Struver

The United Nations Secretary-General’s High-Level Panel on Access to Medicines today issued its final report. The main report was accompanied by eleven pages of additional commentary, including ares of dissent from six panel members, plus additional explanations of the process. The panel was asked to address the policy incoherence from granting monopolies for products on Read more about UN High-Level Panel Endorses Delinkage of R&D Costs from Prices of Drugs and Vaccines[…]

GSK CEO Andrew Witty on “Exploring Delinking the R&D Charge”

Posted on 13 September 201624 April 2017 by James Love

At a March 17, 2016, Center for Strategic and International Studies (CSIS) event in Washington, D.C., on “The Bio-Pharma Industry and Society,” Sir Andrew Witty’s keynote address included a discussion of GSK’s decision to explore the delinkage of R&D costs from drug prices. Witty suggested that delinkage could initially be implemented in the context of Read more about GSK CEO Andrew Witty on “Exploring Delinking the R&D Charge”[…]

Innovation and Access Requires “Delinkage”

Posted on 13 September 201613 September 2016 by James Love

By Ellen ‘t Hoen LLM. Medicines Law & Policy and Global Health Unit, University Medical Center Groningen, University of Groningen, The Netherlands. September 13, 2016 Solving the problems of access to high priced medicines is not possible without some serious new thinking about the way we finance the development of new medicines. Today’s predominant model Read more about Innovation and Access Requires “Delinkage”[…]

The Economics of Delinkage

Posted on 11 September 201613 September 2016 by James Love

By Dean Baker, Co-Director, the Center for Economic and Policy Research (CEPR) September 11, 2016 Every economist knows that trade tariffs are bad because they raise the price of the protected product above the free market price. The story is the same with patent monopolies on prescription drugs. However, there are two big differences. Tariffs Read more about The Economics of Delinkage[…]

Senator Bernie Sanders Reaffirms Support for Delinkage

Posted on 10 September 201612 September 2016 by James Love

In a policy statement on HIV AIDS and in a series of tweets, Senator Bernie Sanders reaffirmed his support of the delinkage of R&D costs from drug prices. This is from Senator Sander’s campaign 2016 statement on “Working to Create an AIDS and HIV-Free Generation.” THE PRIZE PLAN FOR HIV/AIDS As president, Bernie will Read more about Senator Bernie Sanders Reaffirms Support for Delinkage[…]